USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Aug 8, 2022 | Jun 2022 | - | - | $-0.27 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Aug 8, 2022 | Jun 2022 | - | - | $21.97M |
Adamas Pharmaceuticals, Inc's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 8 | $-0.37 | $-0.75 | $0.41 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 0 | $-0.36 | $-0.36 | $-0.36 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 8 | $127.11M | $105.00M | $150.10M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $-0.23 | $-0.43 | -87.94% |
| Aug 9, 2021 | Jun 2021 | $-0.30 | $-0.27 | 8.88% |
| May 10, 2021 | Mar 2021 | $-0.46 | $-0.36 | 21.36% |
| Feb 23, 2021 | Dec 2020 | $-0.52 | $-0.64 | -23.67% |
| Nov 5, 2020 | Sep 2020 | $-0.48 | $-0.42 | 12.95% |
| Aug 6, 2020 | Jun 2020 | $-0.61 | $-0.37 | 39.34% |
| May 7, 2020 | Mar 2020 | $-0.77 | $-0.59 | 23.38% |
| Feb 25, 2020 | Dec 2019 | $-0.83 | $-0.83 | 0.30% |
| Nov 7, 2019 | Sep 2019 | $-0.87 | $-0.99 | -13.36% |
| Aug 8, 2019 | Jun 2019 | $-0.99 | $-0.90 | 8.63% |
| May 9, 2019 | Mar 2019 | $-1.15 | $-1.08 | 5.73% |
| Mar 4, 2019 | Dec 2018 | $-1.32 | $-1.06 | 19.70% |
| Nov 1, 2018 | Sep 2018 | $-1.34 | $-1.22 | 9.16% |
| Aug 2, 2018 | Jun 2018 | $-1.41 | $-1.26 | 10.78% |
| May 3, 2018 | Mar 2018 | $-1.37 | $-1.35 | 1.36% |
| Feb 22, 2018 | Dec 2017 | $-1.18 | $-1.28 | -8.60% |
| Nov 2, 2017 | Sep 2017 | $-0.98 | $-1.04 | -6.48% |
| Aug 8, 2017 | Jun 2017 | $-0.81 | $-0.93 | -15.28% |
| May 9, 2017 | Mar 2017 | $-0.71 | $-0.72 | -1.88% |
| Feb 28, 2017 | Dec 2016 | $-0.80 | $-0.68 | 15.42% |
| Nov 3, 2016 | Sep 2016 | $-0.83 | $-0.66 | 20.07% |
| Aug 4, 2016 | Jun 2016 | $-0.71 | $-0.78 | -10.23% |
| May 10, 2016 | Mar 2016 | $-0.74 | $-0.65 | 12.16% |
| Feb 23, 2016 | Dec 2015 | $-0.86 | $-0.58 | 32.87% |
| Nov 12, 2015 | Sep 2015 | $-0.83 | $-0.81 | 2.41% |
| Aug 11, 2015 | Jun 2015 | $-0.72 | $-0.78 | -8.33% |
| May 13, 2015 | Mar 2015 | $-0.74 | $-0.69 | 6.76% |
| Mar 3, 2015 | Dec 2014 | $-0.24 | $0.50 | 308.33% |
| Nov 4, 2014 | Sep 2014 | $-0.44 | $-0.57 | -29.55% |
| Aug 7, 2014 | Jun 2014 | $0.81 | $0.88 | 8.64% |
| May 14, 2014 | Mar 2014 | - | $-0.67 | - |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 23, 2021 | Dec 2020 | $-1.91 | $-2.02 | - |
| Feb 25, 2020 | Dec 2019 | $-3.83 | $-3.80 | - |
| Mar 4, 2019 | Dec 2018 | $-5.13 | $-4.89 | - |
| Feb 22, 2018 | Dec 2017 | $-3.88 | $-3.97 | - |
| Feb 28, 2017 | Dec 2016 | - | $-2.77 | - |
| Feb 23, 2016 | Dec 2015 | - | $-2.86 | - |
| Mar 3, 2015 | Dec 2014 | - | $0.14 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 10, 2021 | Sep 2021 | $24.77M | $25.90M | 1.05% |
| Aug 9, 2021 | Jun 2021 | $21.97M | $21.97M | 1.00% |
| May 10, 2021 | Mar 2021 | $20.02M | $19.31M | 0.96% |
| Feb 23, 2021 | Dec 2020 | $20.96M | $21.01M | 1.00% |
| Nov 5, 2020 | Sep 2020 | $20.95M | $20.18M | 0.96% |
| Aug 6, 2020 | Jun 2020 | $15.32M | $18.79M | 1.23% |
| May 7, 2020 | Mar 2020 | $15.13M | $14.48M | 0.96% |
| Feb 25, 2020 | Dec 2019 | $15.49M | $16.35M | 1.06% |
| Nov 7, 2019 | Sep 2019 | $14.07M | $13.93M | 0.99% |
| Aug 8, 2019 | Jun 2019 | $12.88M | $12.69M | 0.99% |
| May 9, 2019 | Mar 2019 | $12.31M | $11.66M | 0.95% |
| Mar 4, 2019 | Dec 2018 | $13.26M | $13.31M | 1.00% |
| Nov 1, 2018 | Sep 2018 | $10.17M | $10.61M | 1.04% |
| Aug 2, 2018 | Jun 2018 | $7.57M | $7.57M | 1.00% |
| May 3, 2018 | Mar 2018 | $1.60M | $2.55M | 1.60% |
| Feb 22, 2018 | Dec 2017 | $840.00K | $568.00K | 0.68% |
| Nov 2, 2017 | Sep 2017 | $30.00K | $1.00K | 0.03% |
| Aug 8, 2017 | Jun 2017 | $40.00K | $2.00K | 0.05% |
| May 9, 2017 | Mar 2017 | - | $0.00 | - |
| Feb 28, 2017 | Dec 2016 | - | $37.00K | - |
| Nov 3, 2016 | Sep 2016 | - | $138.00K | - |
| Aug 4, 2016 | Jun 2016 | - | $222.00K | - |
| May 10, 2016 | Mar 2016 | - | $175.00K | - |
| Feb 23, 2016 | Dec 2015 | - | $524.00K | - |
| Nov 12, 2015 | Sep 2015 | - | $768.00K | - |
| Aug 11, 2015 | Jun 2015 | - | $398.00K | - |
| May 13, 2015 | Mar 2015 | - | $226.00K | - |
| Mar 3, 2015 | Dec 2014 | - | $30.30M | - |
| Nov 4, 2014 | Sep 2014 | - | $215.00K | - |
| Aug 7, 2014 | Jun 2014 | - | $25.15M | - |
| May 14, 2014 | Mar 2014 | - | $176.00K | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 23, 2021 | Dec 2020 | $74.39M | $74.46M | 0.10% |
| Feb 25, 2020 | Dec 2019 | $53.67M | $54.64M | 1.80% |
| Mar 4, 2019 | Dec 2018 | $33.92M | $34.05M | 0.37% |
| Feb 22, 2018 | Dec 2017 | $650.00K | $571.00K | -12.15% |
| Feb 28, 2017 | Dec 2016 | - | $572.00K | - |
| Feb 23, 2016 | Dec 2015 | - | $1.92M | - |
| Mar 3, 2015 | Dec 2014 | - | $55.85M | - |
ADMS's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 30, 2022.
Adamas Pharmaceuticals, Inc's previous earnings date was May 9, 2022 for its fiscal quarter ended Mar 31, 2022.
Adamas Pharmaceuticals, Inc's previous annual earnings date was Feb 23, 2021 for its fiscal year ended Dec 31, 2020.
ADMS's earnings per share (EPS) was $-2.02, missing the consensus analysts forecast of $-1.91 by 5.76% , and higher than the previous year's EPS (Dec 2019) by -46.84%.
Revenues were $74.46M, better than the forecast of $74.39M by 0.10%, and up by 36.28% from previous year's revenue.
The company reported a net income of $-57.40M.
Adamas Pharmaceuticals, Inc reported a free cash flow of $-50.71M for its fiscal year, compared to $-80.80M a year ago.
The company ended the fiscal year with $129.96M in total debt, an increase of 1.76% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
